-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Firzacorvir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2243747-96-6.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2243747-96-6 |
| Description | Firzacorvir is a cyclic sulfamide compound that regulates HBV core protein and has anti-HBV activity with an EC50 of <1 μM. |
Product Information
| Synonyms | (3S,5R)-N-(3-chloro-4-fluorophenyl)-2-methyl-5-(5-(1-methyl-1H-imidazol-4-yl)thiazol-2-yl)-1,2,6-thiadiazinane-3-carboxamide 1,1-dioxide |
| IUPAC Name | (3S,5R)-N-(3-chloro-4-fluorophenyl)-2-methyl-5-[5-(1-methylimidazol-4-yl)-1,3-thiazol-2-yl]-1,1-dioxo-1,2,6-thiadiazinane-3-carboxamide |
| Molecular Weight | 484.96 |
| Molecular Formula | C18H18ClFN6O3S2 |
| Canonical SMILES | CN1C=C(N=C1)C2=CN=C(S2)C3CC(N(S(=O)(=O)N3)C)C(=O)NC4=CC(=C(C=C4)F)Cl |
| InChI | InChI=1S/C18H18ClFN6O3S2/c1-25-8-14(22-9-25)16-7-21-18(30-16)13-6-15(26(2)31(28,29)24-13)17(27)23-10-3-4-12(20)11(19)5-10/h3-5,7-9,13,15,24H,6H2,1-2H3,(H,23,27)/t13-,15+/m1/s1 |
| InChIKey | XVKTYEAUJPZPDZ-HIFRSBDPSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| Complexity | 774 |
| Exact Mass | 484.0554367 |
| Target | HBV |
| XLogP3-AA | 1.4 |
